A phase II trial of an Indoleamine2,3, dioxygenase-1 (IDO1) inhibitor (INCB024360) plus a multipeptide melanoma vaccine in patients with advanced melanoma (MELITAC 12.1)
This pilot phase II trial studies how well INCB024360 (indoleamine 2,3-dioxygenase 1 [IDO1]
inhibitor INCB024360) and vaccine therapy work in treating patients with stage III-IV
melanoma. IDO1 inhibitor INCB024360 may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth. Vaccines made from peptides and antigens may help the
body build an effective immune response to kill tumor cells. Giving IDO1 inhibitor
INCB024360 with vaccine therapy may be an effective treatment for advanced melanoma.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.